Clinical outcome of older adults with acute myeloid Leukemia: An analysis of a large tertiary referral Center over two decades.

Journal of Geriatric Oncology
Jana IhlowJörg Westermann

Abstract

In older adults with acute myeloid leukemia (AML), the overall outcome is still dismal and long-term data on survival are scarce, particularly outside of clinical trials. Here, we assess characteristics, prognostic factors and long-term survival in patients ≥60 years who were treated for AML at our center over the past 17 years. 590 older adults with newly diagnosed AML were characterized according to Eastern Cooperative Oncology Group (ECOG) score, Charlson comorbidity index (CCI), European LeukemiaNet (ELN) risk, type of therapy, serum ferritin (SF) and further baseline characteristics. Survival analysis was performed accordingly. Median age was 68 years and most patients were in good general condition. Median follow-up was 55.8 months. Of all patients, 66% received intensive chemotherapy (IC) +/- allogeneic hematopoietic stem cell transplantation (allo-HSCT). The remaining cohort received palliative chemotherapy (PC, 26%) or best supportive care only (BSC, 8%). Enrollment rate for interventional clinical trials was 26%. 5-year overall survival (OS) and relapse-free survival (RFS) were 18% (median 12.5 months) and 11,5% (median 10.0 months). Long-term survival was independently influenced by ECOG score, ELN risk group, baseli...Continue Reading

References

Aug 1, 1996·Controlled Clinical Trials·M Schemper, T L Smith
Aug 31, 2001·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R C Bland, S C Newman
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas BüchnerWolfgang Hiddemann
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ziyi LimTheo M De Witte
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Sep 24, 2010·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Stefano VolpatoJack M Guralnik
Mar 3, 2012·Blood·Gunnar JuliussonUNKNOWN Swedish Acute Leukemia Registry Group
Mar 13, 2012·International Journal of Hematology·Shohei KikuchiJunji Kato
Jul 10, 2012·Haematologica·Betul Oran, Daniel J Weisdorf
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krzysztof MrózekClara D Bloomfield
Feb 4, 2014·British Journal of Haematology·Ruediger LierschUtz Krug
Nov 7, 2014·F1000prime Reports·Margaret M Showel, Mark Levis
Dec 18, 2014·Blood·Gert Ossenkoppele, Bob Löwenberg
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lene Sofie Granfeldt ØstgårdJan Maxwell Nørgaard
Nov 4, 2015·Journal of Geriatric Oncology·Bernard TawfikHeidi D Klepin
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lars BullingerHartmut Döhner
Jan 4, 2018·Blood Advances·Alexander E Perl

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

International Journal of Hematology
Masamitsu Yanada, Tomoki Naoe
Critical Reviews in Oncology/hematology
John E Godwin, Scott E Smith
© 2021 Meta ULC. All rights reserved